Identifying New Antigenic Domains on Glycoprotein B of Human Cytomegalovirus
Author Information
Author(s): Pötzsch Sonja, Spindler Nadja, Wiegers Anna-Katharina, Fisch Tanja, Rücker Pia, Sticht Heinrich, Grieb Nina, Baroti Tina, Weisel Florian, Stamminger Thomas, Martin-Parras Luis, Mach Michael, Winkler Thomas H.
Primary Institution: Friedrich-Alexander Universität Erlangen-Nürnberg, Germany
Hypothesis
Characterizing the B-cell response in healthy infected individuals could aid in the design of optimal vaccines and therapeutic antibodies against HCMV.
Conclusion
The study found that most gB-specific antibodies do not neutralize the virus, while neutralizing antibodies target two previously uncharacterized domains.
Supporting Evidence
- Over 90% of gB-specific antibodies do not neutralize the virus.
- Most neutralizing antibodies bind to epitopes not located within previously characterized antigenic domains.
- Two new protein domains were identified as targets for neutralizing antibodies.
Takeaway
Most antibodies made by people infected with a virus called HCMV don't help fight the virus, but some do target new parts of the virus that could help make better vaccines.
Methodology
The study analyzed the antibody repertoire against glycoprotein B (gB) of HCMV by isolating gB-specific memory B cells from healthy HCMV-seropositive donors and testing the produced antibodies for reactivity and neutralization capacity.
Limitations
The study was limited to a small number of donors and may not represent the entire population's immune response.
Participant Demographics
Healthy HCMV-seropositive individuals.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website